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Prostate cancer (CaP) represents a major leading cause of morbidity and mortality in the Western world. Elevated
cholesterol levels, resulting from altered cholesterol metabolism, have been found in CaP cells. Seladin-1 (SELective
Alzheimer Disease INdicator-1)/DHCR24 is a recently described gene involved in cholesterol biosynthesis. Here, we
demonstrated the androgen regulation of seladin-1/DHCR24 expression, due to the presence of androgen responsive
element sequences in its promoter region. In metastatic androgen receptor-negative CaP cells seladin-1/DHCR24
expression and cholesterol amount were reduced compared to androgen receptor-positive cells. In tumor samples from
61 patients who underwent radical prostatectomy the expression of seladin-1/DHCR24 was significantly higher with
respect to normal tissues. In addition, in cancer tissues mRNA levels were positively related to T stage. In tumor specimens
from 23 patients who received androgen ablation treatment for 3 months before surgery seladin-1/DHCR24 expression
was significantly lower with respect to patients treated by surgery only. In conclusion, our study demonstrated for the
first time the androgen regulation of the seladin-1/DHCR24 gene and the presence of a higher level of expression in CaP
tissues, compared to the normal prostate. These findings, together with the results previously obtained in metastatic
disease, suggest an involvement of this gene in CaP.
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Prostate cancer (CaP) is a major leading cause of male cancer
related death, second only to lung cancer, and represents 10%
of all cancer deaths in men in the United States. In this
country, one in six men will be diagnosed with CaP during
their life time.1 In the past years there has been a strong
increase in the proportion of patients diagnosed with CaP
confined to the gland, as a consequence of widespread
detection strategies based on the measurements of the level of
prostate-specific antigen (PSA) in the blood.2 After radical
prostatectomy, the increase of serum PSA is a marker of
biochemical recurrence. As PSA is an androgen-regulated
gene, biochemical recurrence of CaP by PSA relapse is in
itself evidence of the androgen receptor (AR) dependence of
the tumor. The key role of androgen signalling has been
further highlighted by the chromosomal rearrangements
recently identified in the majority of CaP.3 Following these
unbalanced rearrangements, the coding sequences of ERG, a
member of ETS transcription factors family, are leaded under
the regulatory sequences of the androgen-regulated gene
TMPRSS2.3 The newly formed fusion gene thus becomes a
candidate oncogene in CaP.4 Recently, Hendriksen et al5
observed that in primary CaP specimens reduced expression
levels of AR-related genes, including seladin-1 (for SELective
Alzheimer Disease INdicator-1; also known as DHCR24 for
3-b-hydroxysterol-d-24-reductase), correlated with an in-
creased risk to develop metastases. DHCR24 is the enzyme
that converts desmosterol into cholesterol.6 The role of
seladin-1/DHCR24 in cholesterol biosynthesis has been
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recently linked to membrane cholesterol content and lipid
rafts regulation.7 Lipid rafts are cholesterol-rich membrane
compartments, that are able to selectively retain or exclude
specific cohorts of proteins affecting intracellular signalling.
Elevated cholesterol levels in CaP cell membranes have been
linked with lipid rafts deregulation and consequent activation
of signalling pathways that promote growth advantage.8 An
additional property of seladin-1/DHCR24 is to inhibit the
activation of caspase 3, a key modulator of apoptosis.9
However, another study indicated that this multifaced pro-
tein may have a more complex role in cell apoptosis. In fact,
following oncogenic and oxidative stress, seladin-1/DHCR24
was found to bind P53 N-terminal domain and to displace E3
ubiquitin ligase Mdm2 from P53, thus resulting in P53
accumulation.10 Altered levels of seladin-1/DHCR24 expression
have been associated to a more aggressive phenotype in
melanomas,11 adrenal cortex tumors12 and pituitary adeno-
mas.13 It has been hypothesized that the androgen-respon-
siveness of seladin-1/DHCR24 may be due to the presence of
an androgen responsive element (ARE) found in the gene
promoter region,14 even though its functional activity has
never been proven. In the present study we first focused on
the functional activity of seladin-1/DHCR24 ARE sequences
by a luciferase reporter gene assay in order to prove that these
sequences mediate the androgen-responsiveness of seladin-1/
DHCR24 in prostate cells. With regard to this issue, we then
investigated the expression levels of this gene and the mod-
ifications of cell cholesterol content in AR-positive and AR-
negative CaP cell lines. Finally, we determined the amount of
seladin-1/DHCR24 mRNA and protein in tumor prostate
specimens from radical prostatectomy in order to evaluate
whether the expression of this gene may be implicated in CaP.
MATERIALS AND METHODS
Specimens, Clinical Data and Prostate Cancer Cell Lines
A total of 61CaP samples were obtained from 61 patients
undergoing radical prostatectomy at the University of Flor-
ence and University of Rome ‘La Sapienza’ after informed
consent of patients and prior institutional review boards
approval. After complete staging procedure the option of
radical prostatectomy was offered to all patients who met
universally accepted criteria.15 Biochemical recurrence was
defined as a PSA level 40.5 ng/ml at any follow-up visit.
Fresh CaP tissue was harvested according to Bova et al.16
Frozen sections were used to confirm that the tumor samples
contained at least 70% of cancer cells. For control, we used
normal prostate tissue excised from the same prostates.
Histologic review of radical prostatectomy specimens was
performed by the same pathologist. Pathologic stage was
assigned according to the 2002 TNM classification.17 Tumor
grade was assessed by the Gleason system on surgical
samples. Fresh prostate tissue was harvested according to
standardized procedures. The frozen tissue blocks were
sectioned and collected for RNA extraction. Additional 24
CaP samples from patients, who received androgen ablation
treatment before surgery based on the decision of the
urologist, were included in the study in order to determine
the expression of the seladin-1/DHCR24 gene.
In addition, CaP cell lines were included in the study. We
performed analyses by using the AR-negative cell lines PC3,
DU145 and the AR-positive cell lines LnCap, DU145-AR18
and PC3-AR19 both stably transfected with hAR.
Quantitative Real-Time RT-PCR for Seladin-1/DHCR24
Total RNA was isolated from paired tumor and normal
tissues with Trizol reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. Total RNA was
also obtained from the CaP cell lines. The concentration was
determined spectrophotometrically with Nanodrops ND-
1000. Total RNA (0.5 mg) was reverse transcribed into cDNA
by using TaqMan reverse transcription reagents with random
examers (Applied Biosystems Inc., Foster City, CA, USA).
The profile of the reverse transcription reaction was 10 min at
251C, 30 min at 481C and 5 min at 951C. The absolute
quantification of seladin-1/DHCR24 RNA was performed by
real-time RT-PCR. TaqMan primers, probe and thermal
cycling conditions were as previously described.12 Primers and
probe for PSA (Unigene ID Hs.171995) were Assay-On-
Demand gene expression products (assay no. Hs00426859_g1)
purchased from Applied Biosystems. The human GAPDH
(Unigene ID Hs.479728) mRNA was chosen as the reference
gene (Hs02758991_g1; Applied Biosystems). PCR mixture
(25 ml final volume) consisted of 1 final concentration of
Assay-On-Demand mix, 1 final concentration of Universal
PCR Master Mix (Applied Biosystems) and 20 ng cDNA.
Each measurement was carried out in triplicate. The mRNA
quantitation was based on the comparative Ct method
according to the manufacturer’s instructions (Applied
Biosystems) and data were normalized to GAPDH expression.
Plasmids and Transient Transfection Assays
The human seladin-1/DHCR24 promoter sequence from
4384 to 2892 containing the ARE element was amplified
by PCR from human genomic DNA using the left primer
with the KpnI restriction enzyme site and the right primer
with the NheI site: 50-ggtacctcttggtcaatctgcattcg-30 and
50-gctagcctggagtcaaagcagcttcc-30. The 1483 bp PCR product
was subcloned into the pCRII TOPO vector (Invitrogen, SRL,
Milan, Italy), sequenced and cut out by digestion with KpnI
and NheI.20 The excided sequence was successively cloned
into the KpnI/NheI site of the tataluciferase vector21
containing a minimal TATA promoter upstream of a
luciferase reporter gene, to obtain selaprom-tataluc plasmid.
CHO cell line (American Type Tissue Collection, Manassas,
VA, USA) and human benign prostate hyperplasia (BPH)
cells22 were plated in 24-well plates and were transfected with
400 ng of reporter (selaprom-tataluc plasmid), 80 ng of AR
(pSVAR0 expression plasmid),23 and 10 ng of the pGL
4.75 Renilla luciferase normalization vector (Promega
Corp., Madison, WI, USA) by using Lipofectamin 2000
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(Invitrogen). Cells were treated with ethanol vehicle or R1881
(10 nM, 24 h) (NEN; PerkinElmer, Waltham, MA, USA).
Luciferase reporter assays were performed by using the Dual-
Glo Luciferase Reporter Assay System (Promega Corp.).
Firefly luciferase light output was normalized by Renilla
luciferase output after subtraction of background light
output by Victor 3 (PerkinElmer).
Immunohistochemistry for Seladin-1/DHCR24
Sections (4-mm thick) were obtained from formalin-fixed and
paraffin-embedded radical prostatectomy specimens. The
sections were deparaffinized in Bio-Clear (Bio-Optica, Milan,
Italy) and hydrated with graded ethanol. To block en-
dogenous peroxidase activity, slides were treated with 3.0%
hydrogen peroxidase in distilled water for 10 min. Antigen
retrieval was routinely performed by immersing the sections
in EDTA buffer pH 8.0 in thermostatate bath (DAKO A/S,
Glostrup, Denmark) at 981C for 30 min. Then the tissue
sections were stained with a polyclonal antibody against
seladin-1/DHCR249 at 1:50 dilution and incubated for 2 h at
room temperature. Primary antibody bound to antigen was
detected with a standard streptavidin–biotin–peroxidase
technique (LabVision, Fremont, CA, USA) and visualized
with 3,30-diaminobenzidine (BioGenex, San Ramon, CA,
USA) as chromogen. Nuclei were counterstained with May-
er’s hematoxylin. Sections of strongly positive adrenal cortical
adenoma were used as positive controls whereas negative
controls were performed by replacing the primary antibody
with a nonimmune serum at the same concentration.
Cholesterol Measurement
The amount of cholesterol was determined by gas chromato-
graphy–mass spectrometry (GC/MS) using stigmasterol as
internal standard. Cells were harvested and homogenized as
previously described.24 The protein concentration was
determined by using the Bradford method. Proteins (5 mg)
were used for cholesterol determination. After the addition of
stigmasterol (1000 ng), sterols were saponified in 1 N NaOH
in MeOH at 401C for 60 min and successively extracted with
n-hexane. After evaporation, sterols were derivatized in N,O-
bis(trimethylsilyl)-trifluoroacetamide (BSTFA) with 10%
trimethyl-chlorosilane at 701C for 30 min. BSTFA solution
(2 ml) was automatically injected for analysis. Calibration
curve of cholesterol (range 50–2000 ng) with 1000 ng of
stigmasterol as internal standard was used for cholesterol
quantification. Each point was obtained by adding the
appropriate quantities of cholesterol and internal standard
and performing the same procedure of the samples. The
experimental conditions for the samples analysis were as
previously reported.24
Statistical Analysis
Statistical analysis was performed using the Statistical Pack-
age for the Social Sciences software (SPSS, Evanston, IL,
USA). Statistical analysis of cell lines data was performed by
t-test. The clinical and pathologic variables were explored for
the associations with seladin-1/DHCR24 levels. Owing to
nonparametric distribution, Mann–Whitney U-test and
Wilcoxon’s rank sum text for unpaired data were performed
and correlation between two variables was ascertained by
Spearman’s correlation test. P-value o0.05 was considered
statistically significant. Results were expressed as median or
mean±s.e. unless otherwise stated.
RESULTS
Androgen-Responsiveness of ARE Sequences in Seladin-1/
DHCR24 Promoter Region
We first focused on the functional activity of seladin-1/
DHCR24 ARE sequences by a luciferase reporter gene system.
When CHO cells were transiently transfected with sela-
prom-tataluc plasmid and pSVAR0 expression plasmid, and
treated with the AR-agonist R1881 (10 nM), the luciferase
activity of the cells showed a threefold increase compared to
the basal level. The ARE-dependent transactivation by R1881
determined a marked increase (fivefold) of luciferase activity
also in BPH cells (Figure 1).
Seladin-1/DHCR24 Expression in Prostate Cells and
Correlation with Cell Cholesterol Amount
In order to investigate the androgen responsiveness of sela-
din-1/DHCR24 in prostate cell models, we measured the
expression level of this gene by quantitative real-time
RT-PCR (qRT-PCR) in the AR-positive CaP cell line
DU145-AR18 and in BPH cells22 expressing endogenous AR.
Treatment with R1881 (10 nM, 24 h) induced a 5- and
CHO
BPH
0 1 2 3 4 5 6 7
Luciferase activity normalized (fold increase)
∗
∗
R1881 10 nM
EtOH
Figure 1 Functional analysis of seladin-1/DHCR24 ARE. CHO cells and
human benign prostate hyperplasia (BPH) cells were transfected with
selaprom-tataluc construct, pSVAR0 expression plasmid and pGL 4.75. Cells
were treated with ethanol vehicle (EtOH) or R1881 (10 nM, 24 h). Firefly
luciferase light output was normalized by Renilla luciferase output.
Measurements, reported as fold increase vs vehicle, represent the
mean±s.e. of three independent experiments. Statistical analysis was
performed by t-test; *Po0.05 vs vehicle.
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2.5-fold increase of seladin-1/DHCR24 expression vs
untreated cells, respectively (Figure 2a). To further evaluate
the involvement of AR in modulating seladin-1/DHCR24
expression and to assess the presence of a correlation with cell
cholesterol content, we measured both the gene expression
level by qRT-PCR and the cell cholesterol amount by GC/MS
in CaP cell lines. We used AR-negative, ie DU145-Mock,
PC3-wt and PC3-Neo, and AR-positive CaP cells, ie LNCaP,
DU145-AR and PC3-AR. The highly invasive AR-negative
cells were characterized by a lower expression of seladin-1/
DHCR24 with respect to the AR-positive CaP cells (Figure 2b).
Moreover, this different expression was paralleled by a
modification of cholesterol content. In fact, in DU145-Mock
total cholesterol was significantly lower compared to LNCaP
cells (9.58±0.75 vs 33.06±3.78 ng, mean±s.e., Po0.01,
t-test). These cell lines were selected as representative of cells
not expressing or naturally expressing AR. Another cell line
not expressing AR (ie PC3) was used for cholesterol mea-
surement, and in this case the comparison was made between
wild-type cells and cells in which AR expression was induced
exogenously (PC3-AR). In PC3-AR cells the amount of cell
cholesterol was higher than in PC3-Neo (7.69±0.10 vs
6.31±0.13 ng, mean±s.e., Po0.01, t-test).
Expression of Seladin-1/DHCR24 mRNA and
Immunohystochemical Analysis in Human Normal
and Tumor Prostate Tissues
Until now, no data about the expression of seladin-1/
DHCR24 in CaP tissues vs paired normal tissues are available.
The amount of mRNA for seladin-1/DHCR24 was in-
vestigated in tumor specimens derived from patients who
underwent radical prostatectomy for clinically localized CaP.
By using qRT-PCR we evaluated seladin-1/DHCR24 expres-
sion in a cohort of 61 CaP specimens collected consecutively
at surgery (Table 1). The amount of seladin-1/DHCR24
mRNA was found to be significantly higher in prostate tu-
mors compared to the adjacent normal tissue. The median
expression level in the tumor tissue was 155 fg/mg total RNA
as opposed to 57.6 fg/mg total RNA (P¼ 0.021) in the normal
specimens. In order to confirm that higher mRNA expression
corresponded to increased protein levels and to verify the
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Figure 2 AR regulation of seladin-1/DHCR24 expression in prostate cells.
(a) Expression of seladin-1/DHCR24 in DU145-AR and BPH cells in basal
conditions and after exposure to R1881. (b) Expression of seladin-1/DHCR24
in different human CaP cell lines. The amount of mRNA was measured in
DU145-Mock, PC3, PC3-Neo cell lines (without functional AR, w/o AR) and in
DU145-AR, PC3-AR, LNCaP cells (with functional AR, w AR) and was reported
as fold increase of AR-positive vs AR-negative cells, considered as 1.
Statistical analysis was performed by t-test; *Po0.05 vs control cells.
Table 1 Clinical and pathologic demographics of 61 men with
clinically localized CaP treated by radical prostatectomy
Patients data Surgery (n¼ 61) Biochemical
relapse
Follow-up (n¼ 50) 3–97 months (mean:
48.50 months)
(38%) n¼ 19
Age (n¼ 54) 51–78 years (mean:
54.62 years)
Gleason score p7 n¼ 46 (75%) (24%)
Gleason score 47 n¼ 15 (25%) (60%)
pT2 n¼ 33 (54%) (25%)
pT3-pT4 n¼ 28 (46%) (43%)
Lymph node n¼ 61
Positive n¼ 8 (13.1%) (75%)
Negative n¼ 53 (86.9%) (26.4%)
Surgical margins n¼ 34
Positive n¼ 6 (18%) (33.3%)
Negative n¼ 28 (82%) (32.1%)
Bladder invasion n¼ 34
Positive n¼ 3 (8.8%) (100%)
Negative n¼ 31 (91.1%) (25.8%)
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localization of the protein in CaP sections, immuno-
hystochemistry for seladin-1/DHCR24 was performed on 10
human prostate tissue specimens from our cohort of patients.
A representative experiment is shown in Figure 3. Seladin-1/
DHCR24 staining was detected predominantly in the cyto-
plasm and was expressed only at weak levels within the areas
of normal prostate tissue (see arrows in Figure 3a and b),
whereas a markedly stronger signal was detected in the can-
cerous glandular epithelia (Figure 3a and b). Sections of
human adrenal cortical adenoma, which expresses high levels
of seladin-1/DHCR24,12 served as the positive control (Figure 3c).
Control experiments by using nonimmune serum gave a
negligible signal (Figure 3d). In addition, qRT-PCR showed
that the expression of seladin-1/DHCR24 in prostate tumor
samples is directly related to the mRNA levels of PSA
(R¼ 0.641, P¼ 0.0001), in agreement with the androgen-
responsiveness of the gene, as observed in CaP cell lines
(Figure 4).
Figure 3 Immunohistochemistry for seladin-1/DHCR24 performed on formalin-fixed and paraffin-embedded CaP specimens at two different original
magnifications (a)  100 and (b)  50. The arrows indicate areas of normal prostate tissue. (c) Section of human adrenal cortical adenoma, which strongly
expresses seladin-1/DHCR24 protein ( 150). (d) CaP section stained with a nonimmune serum, used as a negative control.
Seladin-1/DHCR24 in prostate cancer
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With regard to the clinical parameters of the patients,
higher levels of seladin-1/DHCR24 expression were sig-
nificantly associated with a higher T stage (P¼ 0.04; Table 2).
A direct correlation between seladin-1/DHCR24 expression
and bladder invasion (P¼ 0.006) was also found, although
the meaning of this finding is limited by the fact that only 3
out of the 34 analyzed histological samples fell into this
category. It has to be said that in patients with locally
advanced disease surgery is considered a possible treatment
only in very selected cases25,26 and therefore the availability of
surgical samples is a very rare event.
Seladin-1/DHCR24 Expression in CaP After Androgen
Ablation Treatment
To gain further insight on the androgen-mediated regulation
of the seladin-1/DHCR24 gene, we examined the levels of
mRNA in CaP specimens of patients treated with androgen
deprivation for 3 months before radical prostatectomy
(n¼ 24). The amount of seladin-1/DHCR24 expression was
significantly lower in this group of patients compared to the
61 patients, who underwent prostatectomy without prior
treatment (P¼ 0.005; Figure 5).
DISCUSSION
Seladin-1/DHCR24 is broadly expressed in most peripheral
tissues, including the prostate,9 and are important in
cholesterol biosynthesis by catalyzing the conversion of
desmosterol into cholesterol.6 Altered levels of expression of
this gene have been detected in different neoplastic diseases11–13
and reduced expression in CaP has been associated with an
increased metastatic risk.5 The androgen-responsiveness of
seladin-1/DHCR24 has been hypothesized to be related to an
ARE identified in the gene promoter region,14 even though
functional evidence was still lacking, so far. This study
investigated the functional activity of seladin-1/DHCR24
Figure 4 Correlation between the amount of seladin-1/DHCR24 and PSA
expression in patients treated by surgery. Statistical analysis was performed
by using Spearman’s correlation test (R¼ 0.641; P¼ 0.0001).
Table 2 Relationship between seladin-1/DHCR24 expression
and clinical features of patients treated by radical
prostatectomy
Clinical features Patients treated by surgery (n¼ 61)
PSA recurrence n¼ 58
No 160.8
Yes 282.5
P¼ 0.73
Stage n¼ 61
pT2 65.8
pT3-T4 239.3
P¼ 0.04
Lymph node n¼ 61
No 168
Yes 230
P¼ 0.6
Surgical margin n¼ 34
No 169
Yes 1217.5
P¼ 0.07
Bladder invasion n¼ 34
No 170
Yes 2691
P¼ 0.006
Gleason score n¼ 61
o7 170
7 92.5
47 28.2
P¼ 0.31
PSA at diagnosis n¼ 38
o9 207.5
X9 239.3
P¼ 0.68
PSA, prostate-specific antigen.
The numbers indicate seladin-1/DHCR24 expression (fg mRNA/mg total RNA,
median value). Statistical analysis was performed by Mann–Whitney test and
Wilcoxon’s rank sum test; n represents the number of CaP patients falling into the
indicated clinical features category. Significant values (Po0.05) are in bold font.
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ARE sequences by a luciferase reporter gene assay. The in-
crease of luciferase activity in response to the AR agonist
R1881 suggests the presence of a classical AR-mediated me-
chanism of transcriptional regulation of seladin-1/DHCR24
expression. This finding was confirmed by the increase of the
amount of transcript elicited by R1881 in AR-positive CaP
and BPH cells.
In order to investigate the relationship between seladin-1/
DHCR24 expression and its enzymatic activity to produce
cholesterol, the expression level of the gene was determined
by qRT-PCR and the total cholesterol amount was measured
by GC/MS. In AR-positive CaP cells the mRNA level of
seladin-1/DHCR24 and the total cholesterol amount were
higher compared to AR-negative cells. These results indicated
that in CaP cell models the expression of seladin-1/DHCR24
paralleled the cholesterol content and that the presence of a
functional AR was associated with higher levels of expression
of the gene. It is now clear that the reexpression of the wild-
type AR contributes to a more differentiated phenotype in
CaP cell lines.19,27 We observed increased levels of seladin-1/
DHCR24 expression/activity following AR reexpression in
AR-negative CaP cells. From this evidence we can speculate
that both the expression and the function of seladin-1/
DHCR24 are modulated by a newly restored androgen
responsiveness. According to our findings, it has been
demonstrated that a deregulated activation of the AR
signalling during progression of CaP may occur also in a
ligand-independent manner, through different mechanisms
involving for instance AR activation by growth factors,
receptor tyrosine kinases through the MAPK or the AKT
pathways, or mutated coregulators.28
With regard to the enzymatic activity of seladin-1/
DHCR24, involving the biosynthesis of cholesterol, it can be
pointed out the fact that this gene may be involved in the
organization of cholesterol-rich detergent-resistant mem-
brane domains (DRMs), namely lipid rafts, as demonstrated
by the observation that a reduced protein content has been
found in DRMs of seladin-1/DHCR24-deficient mouse
brains.7 Interestingly, an involvement of lipid rafts in mod-
ulating cell signalling has been hypothesized. In particular,
expansion of the cholesterol-rich membrane compartment,
within certain limits, is likely to promote the formation of
raft-resident signalling complexes that promote cell pro-
liferation and survival in tumoral cells, including CaP.29
Whereas an association between decreased levels of sela-
din-1/DHCR24 and metastasis incidence has been found,5 no
evidence concerning the expression of this gene in CaP
tissues vs adjacent normal tissues was available, so far.
Therefore, we evaluated the amount of seladin-1/DHCR24
mRNA in specimens consecutively collected at surgery from a
cohort of 61 patients diagnosed for a clinically localized CaP.
The amount of transcript was significantly higher in tumoral
tissues compared to the adjacent normal tissue. Accordingly,
immunohystochemical analysis performed in 10 specimens
showed higher protein expression in tumor glands vs
adjacent normal areas. The analysis of the correlation
between gene expression and clinical–pathological parameters
revealed that increased gene expression was significantly
associated with a higher T stage (T3–T4). This bimodal
variation of seladin-1/DHCR24 expression (ie increased
expression in CaP and reduced expression in metastatic
disease) is in agreement with a similar behavior of a number
of anrogen-responsive genes. In their work, Hendriksen
et al5 highlighted the fact that the expression of about 50% of
the 200 androgen-responsive genes, which were considered,
was upregulated in well-differentiated CaP, whereas the large
majority of them was downregulated in metastatic disease,
in which the AR pathway is disrupted. These results are in
agreement with previous studies, in which gene expression
profiling in CaP tissues was performed.30,31
Finally, in our study the androgen-mediated expression of
seladin-1/DHCR24 was further confirmed in a group of
patients subjected to androgen ablation treatment for
3 months before radical prostatectomy. In fact, in these
specimens the expression levels of this gene were significantly
lower than in patients treated only by surgery. Therefore,
seladin-1/DHCR24 may join a list of genes previously shown
to be downregulated after androgen deprivation, such as
VEGF32 and FGF8b.33
In conclusion, in the present study we have shown for the
first time that seladin-1/DHCR24 is an androgen-dependent
gene regulated by a specific ARE. In addition, the amount of
expression in CaP tissues is higher than in adjacent normal
tissues and appears to be associated with a higher T stage.
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Figure 5 Seladin-1/DHCR24 expression (fg mRNA/mg total RNA, log scale)
evaluated by qRT-PCR in CaP tissues from patients treated by surgery only
or from patients treated by androgen ablation before surgery. Statistical
analysis was performed by using Mann–Whitney test (P¼ 0.005).
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However, further studies designed for instance to overexpress
or silence seladin-1/DHCR24 in in vitro models, as well
as extensive in vivo studies, are necessary to fully elucidate
the involvement of this protein, and therefore of cell lipid
content, in modulating the intracellular pathways involved in
CaP progression.
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